hotspot -WSS

hotspot

author：hotspot 2025-09-30 05:45:55 - browse：8815

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： In Memoriam: Notable people who died in 2023
Next article： Campaign finance charge dropped from case against Sam Bankman

WSS

What AstraZeneca

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Why Novartis is going to walk from its acquisition of MorphoSys

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

hotspot

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD: Venture capital, Gilead, and more M&A

DIEP, the 'gold standard' of breast reconstruction, is under threat

Many immigrants are left out of maternal health programs

In Memoriam: Notable people who died in 2023

A single Democrat is willing to weaken Medicare negotiation power

Moonlake's readout produced a cash windfall. Risks remain

Global cancer cases to surge 77% by 2050, WHO report says

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

hotspot

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Global cancer cases to surge 77% by 2050, WHO report says

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

AstraZeneca stays mum on Medicare drug pricing negotiations

Medicare Advantage plans can’t deny care with AI, CMS warns

Problems with a popular proposal to regulate AI in health care

hotspot

hotspot

focus

focus